Literature DB >> 25896084

Multiple sclerosis and pregnancy in the 'treatment era'.

Sandra Vukusic1, Romain Marignier1.   

Abstract

The influence of pregnancy on the course of multiple sclerosis (MS) has long been controversial; until the end of 1990s, women with MS were discouraged from having children owing to a biased belief that pregnancy would worsen the disease course. Since the first large prospective study in 1998, counselling of women with MS has changed radically, and many patients have attained their desire of motherhood. Although many disease-modifying drugs have come to market in the past two decades, when used during pregnancy and lactation, their beneficial effects on the course of MS have to be balanced with fears concerning potential risks to the fetus or child. The wealth of treatment options and the various associated risks have created a growing need for counselling on family planning for women with MS. Most importantly, such counselling should address the concerns that women with MS might have regarding pregnancy. Second, as soon as a woman starts considering pregnancy, a treatment plan should be established. This plan needs to weigh the risk posed to the fetus by potentially harmful drug exposure, and the risk to the mother from a reappearance of disease activity. Finally, breastfeeding and treatment options after delivery should be discussed to outline the options for prevention of postpartum relapses, and the possible resumption of disease-modifying drugs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25896084     DOI: 10.1038/nrneurol.2015.53

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


  66 in total

1.  Obstetric regional blocks for women with multiple sclerosis: a survey of UK experience.

Authors:  E Drake; M Drake; J Bird; R Russell
Journal:  Int J Obstet Anesth       Date:  2006-02-20       Impact factor: 2.603

2.  Pregnancy outcomes in a woman with neuromyelitis optica.

Authors:  Nasrin Asgari; Tine B Henriksen; Thor Petersen; Søren T Lillevang; Brian G Weinshenker
Journal:  Neurology       Date:  2014-09-19       Impact factor: 9.910

3.  Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.

Authors:  C Papeix; R Depaz; A Tourbah; B Stankoff; C Lubetzki
Journal:  Mult Scler       Date:  2011-06-13       Impact factor: 6.312

4.  Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients.

Authors:  A Kerbrat; E Le Page; E Leray; T Anani; M Coustans; C Desormeaux; C Guiziou; P Kassiotis; F Lallement; D Laplaud; P Diraison; F Rouhart; E Sartori; R Wardi; S Wiertlewski; G Edan
Journal:  J Neurol Sci       Date:  2011-06-12       Impact factor: 3.181

5.  Neuromyelitis optica and pregnancy.

Authors:  Yára Dadalti Fragoso; Tarso Adoni; Denis Bernardi Bichuetti; Joseph Bruno Bidin Brooks; Maria Lucia Brito Ferreira; Enedina Maria Lobato Oliveira; Celso Luis Silva Oliveira; Sonia Beatriz Felix Ribeiro; Alex Eduardo Silva; Fabio Siquineli
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

6.  Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum.

Authors:  M Ringelstein; J Harmel; F Distelmaier; J Ingwersen; T Menge; K Hellwig; B Kieseier; E Mayatepek; H-P Hartung; T Kuempfel; O Aktas
Journal:  Mult Scler       Date:  2013-07-25       Impact factor: 6.312

7.  Influence of pregnancy on neuromyelitis optica spectrum disorder.

Authors:  W Kim; S-H Kim; I Nakashima; Y Takai; K Fujihara; M I Leite; J Kitley; J Palace; E Santos; E Coutinho; A M Silva; Byoung-Joon Kim; Byung-Jo Kim; S-W Ahn; H J Kim
Journal:  Neurology       Date:  2012-04-04       Impact factor: 9.910

8.  Increased risk of multiple sclerosis relapse after in vitro fertilisation.

Authors:  Laure Michel; Yohann Foucher; Sandra Vukusic; Christian Confavreux; Jérome de Sèze; David Brassat; Michel Clanet; Pierre Clavelou; Jean-Christophe Ouallet; Bruno Brochet; Jean Pelletier; Pierre Labauge; Christine Lebrun; Emmanuelle Lepage; Fabienne Le Frere; Marylène Jacq-Foucher; Paul Barriere; Sandrine Wiertlewski; David-Axel Laplaud
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-06-11       Impact factor: 10.154

9.  Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.

Authors:  Sandra Vukusic; Françoise Durand-Dubief; Amandine Benoit; Romain Marignier; Bernard Frangoulis; Christian Confavreux
Journal:  Mult Scler       Date:  2014-10-10       Impact factor: 6.312

10.  Risk of miscarriage among users of corticosteroid hormones: a population-based nested case-control study.

Authors:  Anne-Mette B Bjørn; Rikke B Nielsen; Mette Nørgaard; Ellen A Nohr; Vera Ehrenstein
Journal:  Clin Epidemiol       Date:  2013-08-14       Impact factor: 4.790

View more
  25 in total

1.  Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.

Authors:  Maria Pia Amato; Antonio Bertolotto; Roberto Brunelli; Paola Cavalla; Benedetta Goretti; Maria Giovanna Marrosu; Francesco Patti; Carlo Pozzilli; Leandro Provinciali; Nicola Rizzo; Nicola Strobelt; Gioacchino Tedeschi; Maria Trojano; Giancarlo Comi
Journal:  Neurol Sci       Date:  2017-08-02       Impact factor: 3.307

Review 2.  Contraception for women with multiple sclerosis: Guidance for healthcare providers.

Authors:  Maria K Houtchens; Lauren B Zapata; Kathryn M Curtis; Maura K Whiteman
Journal:  Mult Scler       Date:  2017-03-24       Impact factor: 6.312

Review 3.  An Update on the Use of Disease-Modifying Therapy in Pregnant Patients with Multiple Sclerosis.

Authors:  Caila Vaughn; Aisha Bushra; Channa Kolb; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

4.  The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.

Authors:  Edward J D Webb; David Meads; Ieva Eskytė; Helen L Ford; Hilary L Bekker; Jeremy Chataway; George Pepper; Joachim Marti; Yasmina Okan; Sue H Pavitt; Klaus Schmierer; Ana Manzano
Journal:  Patient       Date:  2020-10       Impact factor: 3.883

5.  Relapses and obstetric outcomes in women with multiple sclerosis planning pregnancy.

Authors:  Leticia Berenguer-Ruiz; Juana Gimenez-Martinez; Antonio Palazón-Bru; Angel Perez Sempere
Journal:  J Neurol       Date:  2019-06-29       Impact factor: 4.849

Review 6.  Management of women with multiple sclerosis through pregnancy and after childbirth.

Authors:  Patricia K Coyle
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

Review 7.  Pregnancy and multiple sclerosis: from molecular mechanisms to clinical application.

Authors:  Stefan M Gold; Rhonda R Voskuhl
Journal:  Semin Immunopathol       Date:  2016-08-08       Impact factor: 9.623

8.  Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database.

Authors:  Magnhild Sandberg-Wollheim; Orit Neudorfer; Augusto Grinspan; Bianca Weinstock-Guttman; Judith Haas; Guillermo Izquierdo; Claire Riley; Amy Perrin Ross; Peleg Baruch; Talya Drillman; Patricia K Coyle
Journal:  Int J MS Care       Date:  2018 Jan-Feb

9.  Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy.

Authors:  Garett Dunsmore; Petya Koleva; Nafiseh Ghobakhloo; Reed Sutton; Lindsy Ambrosio; Xuanyi Meng; Naomi Hotte; Vivian Nguyen; Karen L Madsen; Levinus A Dieleman; Vivian Huang; Shokrollah Elahi
Journal:  J Crohns Colitis       Date:  2019-02-01       Impact factor: 9.071

10.  Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis.

Authors:  Astrid Barataud-Reilhac; Sandrine Kerbrat; Jonathan Roux; Alice Guilleux; Elisabeth Polard; Emmanuelle Leray
Journal:  Neurol Clin Pract       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.